C25H29BrN8O2
Neat
553.47
1638744-06-5; Bromobutane Linagliptin; RefChem:570326; 886-454-8; Linagliptin impurity K; Linagliptin impurity S; N-Des-(2-butyn-1-yl)-N-(3-bromo-2-buten-1-yl) Linagliptin; C25H29BrN8O2; MFCD28501521; CS-0255309; F87835; A1-03390; (R, Z)-8-(3-aminopiperidin-1-yl)-7-(3-bromobut-2-en-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2, 6(3H, 7H)-dione; (R, Z)-8-(3-Aminopiperidin-1-yl)-7-(3-bromobut-2-en-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2, 6(3H, 7H)-dione (Linagliptin Impurity); 8-[(3R)-3-amino-1-piperidyl]-7-[(Z)-3-bromobut-2-enyl]-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2, 6-dione; 8-[(3R)-3-aminopiperidin-1-yl]-7-[(Z)-3-bromobut-2-enyl]-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2 and 6-dione
8-[(3R)-3-aminopiperidin-1-yl]-7-[(Z)-3-bromobut-2-enyl]-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2 and 6-dione
InChI=1S/C25H29BrN8O2/c1-15(26)10-12-33-21-22(30-24(33)32-11-6-7-17(27)13-32)31(3)25(36)34(23(21)35)14-20-28-16(2)18-8-4-5-9-19(18)29-20/h4-5,8-10,17H,6-7,11-14,27H2,1-3H3/b15-10-/t17-/m1/s1